NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ORMP
Oramed Pharmaceuticals Inc.
There isn't enough reported data to score ORMP yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ORMP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Unavailable |
ORMP's profitability is currently strong. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ORMP in the historical PE scenario, which offers more potential upside but is not a forecast.
ORMP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.2x | $4.03 | — |
| Cheap | 1.5x | $5.25 | +30% |
| Fair | 5.7x | $19.40 | +381% |
| Expensive | 85x | $290 | +7101% |
Historical ranges are pointers, not guarantees.
ORMP's PE is 1.2x, but its earnings don't support one, so it isn't a reliable read right now.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ORMP Forward outlook
There aren't enough analyst estimates for ORMP to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ORMP on earnings, with more consistent year-over-year improvement.
ORMP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.43 | +246% |
| Q2 2026 | $4.13 | +$4.75 |
| Q1 2026 | $2.60 | +$3.31 |
| Q4 2025 | $1.50 | +$1.98 |
| Q3 2025 | $0.99 | +$1.03 |
| Q2 2025 | -$0.62 | -272% |
| Q1 2025 | -$0.71 | -745% |
| Q4 2024 | -$0.48 | -443% |
ORMP earned $3.43 per share over the past year, about three times what it earned the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
ORMP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $674K | 0% |
| Q1 2023 | $666K | 0% |
| Q4 2022 | $681K | -25% |
| Q3 2022 | $682K | -0.1% |
| Q2 2022 | $674K | -1% |
| Q1 2022 | $666K | +0.2% |
| Q4 2021 | $904K | +34% |
| Q4 2021 | $674K | 0% |
ORMP's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -225% | N/A |
| Q2 2023 | -562% | +1132 points |
| Q1 2023 | -782% | +908 points |
| Q4 2022 | -1430% | -67 points |
| Q3 2022 | -1201% | -4.9 points |
| Q2 2022 | -1694% | -609 points |
| Q1 2022 | -1689% | -791 points |
| Q4 2021 | -1364% | -632 points |
ORMP's operating margin was −225% last quarter, up 976 points from the same quarter a year ago, near the top of its range since 2020.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ORMP on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORMP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $422K | +$2M |
| Q2 2026 | -$202K | +$3.3M |
| Q1 2026 | -$2.9M | +$602K |
| Q4 2025 | -$468K | +$1.5M |
| Q3 2025 | -$1.6M | +$5.5M |
| Q2 2025 | -$3.5M | -270% |
| Q1 2025 | -$3.5M | -$2M |
| Q4 2024 | -$1.9M | -$501K |
ORMP has burned cash in almost every quarter: −$3M over the past year, against −$11M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ORMP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ORMP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +514K shares |
| 1 year | +0.6% | +241K shares |
| 3 years | +6.4% | +2.6M shares |
| 5 years | +17% | +6.3M shares |
| Available history | +141% | +25.2M shares |
ORMP has 43M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $4M |
| Q3 2025 | $361,000 |
| Q4 2024 | $1.2M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ORMP Net Leverage
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ORMP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 8.9 | Oversold |
ORMP's weekly RSI is 47 (neutral) and its Stochastic is 9 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ORMP PE vs Healthcare Sector
| Metric | ORMP | Sector median | Relative |
|---|---|---|---|
| PE | 1.2x | 26x | 95% below |
| PE % | 10 | 29 | 19 pts below |
ORMP has the edge over NVO on valuation relative to its sector.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ORMP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.22 | 4.5% below |
| 20 week MA | $4.38 | 8% below |
| 50 week MA | $3.89 | 3.6% above |
| 100 week MA | $3.08 | 31% above |
| 200 week MA | $2.83 | 42% above |
ORMP has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
ORMP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.18 | $4.54 | -12% |
| 2021 | $4.54 | $15.5 | +242% |
| 2022 | $15.5 | $11.0 | -29% |
| 2023 | $11.0 | $2.31 | -79% |
| 2024 | $2.31 | $2.37 | +2.6% |
| 2025 | $2.37 | $2.95 | +24% |
| 2026 YTD | $2.95 | $4.03 | +37% |
ORMP has the edge over NVO on returns for 2026, with the stronger performance.